Ultragenyx Pharmaceutical Zukünftiges Wachstum

Future Kriterienprüfungen 2/6

Ultragenyx Pharmaceutical wird ein jährliches Gewinn- und Umsatzwachstum von 50% bzw. 32% prognostiziert. Der Gewinn pro Aktie wird voraussichtlich wachsen um 50.9% pro Jahr. Die Eigenkapitalrendite wird in 3 Jahren voraussichtlich -62.1% betragen.

Wichtige Informationen

50.1%

Wachstumsrate der Gewinne

50.9%

EPS-Wachstumsrate

Biotechs Gewinnwachstum	24.7%
Wachstumsrate der Einnahmen	32.1%
Zukünftige Eigenkapitalrendite	-62.1%
Analystenabdeckung	Good
Zuletzt aktualisiert	19 Jun 2024

Jüngste Aktualisierungen zum künftigen Wachstum

Recent updates

Shareholders Will Probably Hold Off On Increasing Ultragenyx Pharmaceutical Inc.'s (NASDAQ:RARE) CEO Compensation For The Time Being

Jun 12

There's No Escaping Ultragenyx Pharmaceutical Inc.'s (NASDAQ:RARE) Muted Revenues Despite A 28% Share Price Rise

Dec 28

Is There An Opportunity With Ultragenyx Pharmaceutical Inc.'s (NASDAQ:RARE) 47% Undervaluation?

Sep 12

An Intrinsic Calculation For Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Suggests It's 50% Undervalued

May 24

Improved Revenues Required Before Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Shares Find Their Feet

Apr 17

Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Shares Could Be 33% Below Their Intrinsic Value Estimate

Feb 18

Ultragenyx upgraded to buy at Guggenheim as stock trading at discount to biotech peers

Oct 13

Ultragenyx grants stock options, restricted stock units

Oct 05

Ultragenyx Pharmaceuticals: Downward Trajectory Likely To Continue

Sep 02

Ultragenyx sells part of North American royalties on Crysvita to OMERS for $500M

Jul 14

Ultragenyx: Convincing Investment Thesis For This Orphan Drug Developer

Jun 20

We Think Ultragenyx Pharmaceutical (NASDAQ:RARE) Needs To Drive Business Growth Carefully

May 19

Gewinn- und Umsatzwachstumsprognosen

NasdaqGS:RARE - Zukünftige Analystenschätzungen und Finanzdaten der Vergangenheit (USD Millions)
Datum	Umsatz	Gewinne	Freier Cashflow	Bargeld aus operativen Tätigkeiten	Durchschn. Anz. Analysten
12/31/2026	846	-337	-206	-372	15
12/31/2025	618	-492	-331	-415	19
12/31/2024	512	-560	-436	-531	19
3/31/2024	443	-613	-544	-509	N/A
12/31/2023	434	-607	-522	-475	N/A
9/30/2023	410	-635	-553	-481	N/A
6/30/2023	403	-721	-553	-459	N/A
3/31/2023	384	-719	-529	-420	N/A
12/31/2022	363	-707	-527	-380	N/A
9/30/2022	343	-678	-480	-344	N/A
6/30/2022	334	-506	-438	-309	N/A
3/31/2022	332	-470	-416	-297	N/A
12/31/2021	351	-454	-412	-339	N/A
9/30/2021	360	-356	-426	-347	N/A
6/30/2021	359	-351	-411	-349	N/A
3/31/2021	334	-204	-243	-196	N/A
12/31/2020	271	-187	-176	-132	N/A
9/30/2020	215	-256	-175	-142	N/A
6/30/2020	159	-301	-203	-168	N/A
3/31/2020	122	-425	-381	-345	N/A
12/31/2019	104	-403	-370	-345	N/A
9/30/2019	84	-397	-344	-329	N/A
6/30/2019	70	-371	-320	-310	N/A
3/31/2019	59	-325	-304	-297	N/A
12/31/2018	51	-198	-295	-291	N/A
9/30/2018	38	-192	-320	-317	N/A
6/30/2018	26	-183	-313	-309	N/A
3/31/2018	13	-204	-285	-282	N/A
12/31/2017	3	-302	N/A	-254	N/A
9/30/2017	0	-292	N/A	-220	N/A
6/30/2017	0	-277	N/A	-186	N/A
3/31/2017	0	-261	N/A	-177	N/A
12/31/2016	0	-246	N/A	-161	N/A
9/30/2016	0	-230	N/A	-154	N/A
6/30/2016	0	-204	N/A	-156	N/A
3/31/2016	N/A	-177	N/A	-133	N/A
12/31/2015	N/A	-146	N/A	-106	N/A
9/30/2015	N/A	-107	N/A	-78	N/A
6/30/2015	N/A	-84	N/A	-58	N/A
3/31/2015	N/A	-68	N/A	-52	N/A
12/31/2014	N/A	-65	N/A	-45	N/A
9/30/2014	N/A	-67	N/A	-42	N/A
6/30/2014	N/A	-63	N/A	-38	N/A
3/31/2014	N/A	-61	N/A	-36	N/A
12/31/2013	N/A	-50	N/A	-31	N/A

Analystenprognosen zum zukünftigen Wachstum

Einkommen vs. Sparrate: RARE wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Ertrag vs. Markt: RARE wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Hohe Wachstumserträge: RARE wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Einnahmen vs. Markt: RAREDie Einnahmen des Unternehmens (32% pro Jahr) werden voraussichtlich schneller wachsen als der Markt US (8.7% pro Jahr).

Hohe Wachstumseinnahmen: RAREDie Einnahmen des Unternehmens (32% pro Jahr) werden voraussichtlich schneller wachsen als 20% pro Jahr.

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Künftige Eigenkapitalrendite: RARE wird voraussichtlich in 3 Jahren unrentabel sein.

Ultragenyx Pharmaceutical Zukünftiges Wachstum

Future Kriterienprüfungen 2/6

Wichtige Informationen

Jüngste Aktualisierungen zum künftigen Wachstum

Ultragenyx Pharmaceutical Inc. Reaffirms Earnings Guidance for the Year 2024

Ultragenyx Pharmaceutical Inc. Reaffirms Earnings Guidance for the Full Year 2024

Ultragenyx Pharmaceutical Inc. Provides Revenue Guidance for 2024

Ultragenyx Pharmaceutical Inc. Provides Earnings Guidance for the Full Year 2023

Ultragenyx Pharmaceutical Inc. Reaffirms Earnings Guidance for the Full Year 2023

Ultragenyx Pharmaceutical Inc. Reaffirms Earning Guidance for the Full Year 2023

Recent updates

Ultragenyx Pharmaceutical Inc. has completed a Follow-on Equity Offering in the amount of $350.000022 million.

Insider recently sold US$441k worth of stock

Ultragenyx Pharmaceutical Inc. Announces Successful Meeting with the FDA

Ultragenyx Pharmaceutical Inc. and Mereo BioPharma Group plc Announce Positive 14-Month Results from the Phase 2 Portion of the Ongoing Phase 2/3 Orbit Study

Shareholders Will Probably Hold Off On Increasing Ultragenyx Pharmaceutical Inc.'s (NASDAQ:RARE) CEO Compensation For The Time Being

Ultragenyx: Modest Sales Growth, With Multiple Inflection Points Approaching

Ultragenyx Pharmaceutical Inc. Announces Positive Top-Line Results from Phase 3 Study of DTX401 Gene Therapy for Glycogen Storage Disease Type Ia (GSDIa)

We Think Ultragenyx Pharmaceutical (NASDAQ:RARE) Has A Fair Chunk Of Debt

First quarter 2024 earnings: EPS and revenues miss analyst expectations

Ultragenyx Pharmaceutical Inc. Reaffirms Earnings Guidance for the Year 2024

Ultragenyx Pharmaceutical Inc. Announces Completion of Enrollment in Phase 3 Orbit and Cosmic Studies Evaluating Setrusumab (UX143) for the Treatment of Osteogenesis Imperfecta (OI)

Ultragenyx Pharmaceutical Inc., Annual General Meeting, Jun 18, 2024

Ultragenyx Pharmaceutical Inc. Announces Positive Interim Phase 1/2 Data in Patients with Angelman Syndrome After Treatment with GTX-102

Independent Director recently sold US$620k worth of stock

Independent Director notifies of intention to sell stock

Ultragenyx Pharmaceutical Earnings: No Visible Path To Financial Success Yet

Ultragenyx Pharmaceutical Inc. has filed a Follow-on Equity Offering in the amount of $350 million.

Full year 2023 earnings: Revenues and EPS in line with analyst expectations

Ultragenyx Pharmaceutical Inc. Reaffirms Earnings Guidance for the Full Year 2024

Founder notifies of intention to sell stock

Ultragenyx Pharmaceutical Inc. Announces Data Demonstrating Treatment with UX111 Results in Significant Reduction in Heparan Sulfate Exposure in Cerebrospinal Fluid Correlated with Improved Long-term Cognitive Function in Patients with Sanfilippo Syndrome Type A (MPS IIIA)

Will Ultragenyx Pharmaceutical (NASDAQ:RARE) Spend Its Cash Wisely?

Ultragenyx Pharmaceutical Inc. Announces Completion of Dosing Across Stage 1 Cohorts in Pivotal Phase 1/2/3 Cyprus2+ Study Evaluating UX701 Gene Therapy for the Treatment of Wilson Disease

New major risk - Financial position

Mereo Biopharma Group plc Provides Update on Pipeline Progress and Corporate Developments

Ultragenyx Pharmaceutical Inc. Provides Revenue Guidance for 2024

Founder notifies of intention to sell stock

There's No Escaping Ultragenyx Pharmaceutical Inc.'s (NASDAQ:RARE) Muted Revenues Despite A 28% Share Price Rise

Ultragenyx Receives European Commission Decision for Evkeeza® (evinacumab) Expanded Indication in Children Aged 5 Years and Older with Homozygous Familial Hypercholesterolemia (HoFH)

Ultragenyx Pharmaceutical Inc. Provides Earnings Guidance for the Full Year 2023

Third quarter 2023 earnings: EPS and revenues miss analyst expectations

Founder notifies of intention to sell stock

Ultragenyx Pharmaceutical Inc. Announces Program and Pipeline Updates At Analyst Day Including Interim Data from Ongoing Studies in Osteogenesis Imperfecta (Oi), Angelman Syndrome (As) and Wilson Disease

New major risk - Financial position

Ultragenyx and Mereo BioPharma Announce Interim Phase 2 Data from Phase 2/3 Orbit Study Demonstrating Setrusumab (UX143) Significantly Reduced Fracture Rates in Patients with Osteogenesis Imperfecta (OI)

Ultragenyx Pharmaceutical Inc. Launches Evkeeza (Enacumab for Injection) in Canada for the Treatment of Homozygous Familial Hypercholesterolemia (HoFH)

Is There An Opportunity With Ultragenyx Pharmaceutical Inc.'s (NASDAQ:RARE) 47% Undervaluation?

New minor risk - Financial position

Ultragenyx Pharmaceutical Inc. Reaffirms Earnings Guidance for the Full Year 2023

Second quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Ultragenyx Pharmaceutical Inc. Announces Initiation of Dosing in Second Cohort of Pivotal Phase 1/2/3 Cyprus2+ Trial Evaluating UX701 Gene Therapy for the Treatment of Wilson Disease

Ultragenyx Pharmaceutical Inc. Announces Appointment of Howard Horn as Chief Financial Officer, Effective October 16, 2023

Ultragenyx Announces First Patients Dosed in Phase 3 Program Evaluating Setrusumab (UX143) for the Treatment of Osteogenesis Imperfecta (OI)

Ultragenyx Pharmaceutical Inc.(NasdaqGS:RARE) dropped from Russell Small Cap Comp Value Index

Ultragenyx Pharmaceutical Inc. Announces Data from the Dose- Selection Phase 2/3 Orbit Study

An Intrinsic Calculation For Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Suggests It's 50% Undervalued

Insider notifies of intention to sell stock

Ultragenyx Pharmaceutical Inc. Announces U.S. Food and Drug Administration Reviews and Agrees to Protocol Amendment to the Phase 1/2 Study of GTX-102

Ultragenyx Pharmaceutical Inc. Announces Upcoming Data Presentations at American Society of Gene & Cell Therapy 2023 Annual Meeting

First quarter 2023 earnings: EPS and revenues miss analyst expectations

Ultragenyx Pharmaceutical Inc. Reaffirms Earning Guidance for the Full Year 2023

Improved Revenues Required Before Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Shares Find Their Feet

Chief Medical Officer & Executive VP recently sold US$176k worth of stock

Ultragenyx Pharmaceutical Inc. Reaffirms Full Year Earnings Guidance for the Year 2023

Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Shares Could Be 33% Below Their Intrinsic Value Estimate

Full year 2022 earnings: Revenues and EPS in line with analyst expectations

Founder notifies of intention to sell stock

Ultragenyx Pharmaceutical Inc. Provides Revenue Guidance for the Year 2022 and 2023

Senior VP notifies of intention to sell stock

Price target decreased to US$96.83

Ultragenyx Pharmaceutical Inc. Announces Departure of Mardi Dier, Executive Vice President

Consensus EPS estimates fall by 23%

Price target decreased to US$99.28

Third quarter 2022 earnings: EPS and revenues miss analyst expectations

Ultragenyx Pharmaceutical Inc. Provides Revenue Guidance for 2022

Executive VP & CFO notifies of intention to sell stock

Executive VP & CFO recently sold US$133k worth of stock

Ultragenyx upgraded to buy at Guggenheim as stock trading at discount to biotech peers

Ultragenyx grants stock options, restricted stock units